Sponsor

Cullinan Pearl Corp.

United States 1 Main Street Suite 520, 02142-1531, United States

About the sponsor

Cullinan Pearl Corp. focuses on non-small cell lung cancer with a specific emphasis on tumors carrying EGFR exon 20 insertion mutations. Its clinical research in this area is centered on patients with advanced disease and treatment-resistant disease patterns.

EGFR exon 20 insertion mutations
Locally advanced NSCLC
Metastatic lung cancer

The sponsor’s oncology activity is directed toward defining clinically relevant outcomes in a molecularly selected lung cancer population.

About Specializations

Cullinan Pearl Corp. runs clinical trials in conditions such as Non-small cell lung cancer recurrent, Non-small cell lung cancer metastatic, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Non-small cell lung cancer recurrent+1

Not recruiting

Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy

InvestigationalNo placebo